a public health advisory described in paragraph (1).


REFERENCES IN TEXT
Subsection (a), referred to in par. (1), means subsec. (a) of section 206 of Pub. L. 111–353.

CONSTRUCTION
Section was enacted as part of the FDA Food Safety Modernization Act, and not as part of the Federal Food, Drug, and Cosmetic Act which comprises this chapter.

Nothing in this section to be construed to alter jurisdiction and authorities established under certain other Acts or in a manner inconsistent with international agreements to which the United States is a party, see sections 2251 and 2252 of this title.

SUBCHAPTER V—DRUGS AND DEVICES

PART A—DRUGS AND DEVICES

§ 351. Adulterated drugs and devices

A drug or device shall be deemed to be adulterated—

(a) Poisonous, insanitary, etc., ingredients; adequate controls in manufacture

(1) If it consists in whole or in part of any filthy, putrid, or decomposed substance; or
(2)(A) If it has been prepared, packed, or held under insanitary conditions whereby it may have been contaminated with filth, or whereby it may have been rendered injurious to health; or
(B) If it is a drug and the methods used in, or the facilities or controls used for, its manufacture, processing, packing, or holding do not conform to or are not operated or administered in conformity with current good manufacturing practice to assure that such drug meets the requirements of this chapter as to safety and has the identity and strength, and meets the quality and purity characteristics, which it purports or is represented to possess; or
(C) If it is represented to possess as, a device which is subject to the provisions of the Homoeopathic Pharmacopoeia of the United States it shall be subject to the provisions of the Homoeopathic Pharmacopoeia of the United States and not to the Homoeopathic Pharmacopoeia of the United States.

(b) Strength, quality, or purity differing from official compendium

If it purports to be or is represented as a drug the name of which is recognized in an official compendium, and its strength differs from, or its quality or purity falls below, the standard set forth in such compendium. Such determination as to strength, quality, or purity shall be made in accordance with the tests or methods of assay set forth in such compendium, except that whenever tests or methods of assay have not been prescribed in such compendium, or such tests or methods of assay as are prescribed are, in the judgment of the Secretary, insufficient for the making of such determination, the Secretary shall bring such fact to the attention of the appropriate body charged with the revision of such compendium, and if such body fails within a reasonable time to prescribe tests or methods of assay which, in the judgment of the Secretary, are sufficient for purposes of this paragraph, then the Secretary shall promulgate regulations prescribing appropriate tests or methods of assay in accordance with which such determination as to strength, quality, or purity shall be made. No drug defined in an official compendium shall be deemed to be adulterated under this paragraph because it differs from the standard of strength, quality, or purity therefor set forth in such compendium, if its difference in strength, quality, or purity from such standard is plainly stated on its label. Whenever a drug is recognized in both the United States Pharmacopoeia and the Homoeopathic Pharmacopoeia of the United States it shall be subject to the requirements of the United States Pharmacopoeia unless it is labeled and offered for sale as a homoeopathic drug, in which case it shall be subject to the provisions of the Homoeopathic Pharmacopoeia of the United States and not to those of the United States Pharmacopoeia.

(c) Misrepresentation of strength, etc., where drug is unrecognized in compendium

If it is not subject to the provisions of paragraph (b) of this section and its strength differs from, or its purity or quality falls below, that which it purports or is represented to possess.

(d) Mixture with or substitution of another substance

If it is a drug and any substance has been (1) mixed or packed therewith so as to reduce its quality or strength or (2) substituted wholly or in part therefor.

(e) Devices not in conformity with performance standards

(1) If it is, or purports to be or is represented as, a device which is subject to a performance standard established under section 360d of this title unless such device is in all respects in conformity with such standard.
(2) If it is declared to be, purports to be, or is represented as, a device that is in conformity with any standard recognized under section 360d(c) of this title unless such device is in all respects in conformity with such standard.
§ 351  TITLE 21—FOOD AND DRUGS  Page 142

(f) Certain class III devices

(1) If it is a class III device—

(A)(i) which is required by a regulation promulgated under subsection (b) of section 360e of this title to have an approval under such section of an application for premarket approval and which is not exempt from section 360e of this title under section 360j(g) of this title, and

(ii)(I) for which an application for premarket approval or a notice of completion of a product development protocol was not filed with the Secretary within the ninety-day period beginning on the date of the promulgation of such regulation, or

(II) for which such an application was filed and approval of the application has been denied, suspended, or withdrawn, or such a notice was filed and has been declared not completed or the approval of the device under the protocol has been withdrawn;

(B)(i) which was classified under section 360c(f) of this title into class III, which under section 360e(a) of this title is required to have in effect an approved application for premarket approval, and which is not exempt from section 360e of this title under section 360j(g) of this title, and

(ii) which has an application which has been suspended or is otherwise not in effect; or

(C) which was classified under section 360j(f) of this title into class III, which under such section is required to have in effect an approved application under section 360e of this title, and which has an application which has been suspended or is otherwise not in effect.

(2)(A) In the case of a device classified under section 360c(f) of this title into class III and intended solely for investigational use, paragraph 1(1) shall not apply with respect to such device during the period ending on the ninetieth day after the date of the promulgation of the regulations prescribing the procedures and conditions required by section 360j(g)(2) of this title.

(B) In the case of a device subject to a regulation promulgated under subsection (b) of section 360e of this title, paragraph 1(1) shall not apply with respect to such device during the period ending:

(1) on the last day of the thirtieth calendar month beginning after the month in which the classification of the device in class III became effective under section 360e of this title, or

(ii) on the ninetieth day after the date of the promulgation of such regulation, whichever occurs later.

(g) Banned devices

If it is a banned device.

(h) Manufacture, packing, storage, or installation of device not in conformity with applicable requirements or conditions

If it is a device and the methods used in, or the facilities or controls used for, its manufacture, packing, storage, or installation are not in conformity with applicable requirements under section 360j(f)(1) of this title or an applicable condition prescribed by an order under section 360j(f)(2) of this title.

(i) Failure to comply with requirements under which device was exempted for investigational use

If it is a device for which an exemption has been granted under section 360(g) of this title for investigational use and the person who was granted such exemption or any investigator who uses such device under such exemption fails to comply with a requirement prescribed by or under such section.

1997) or 2 years after the date on which the Secretary of Health and Human Services establishes the require-
ments described in subsection (c)(1)(B) [section 1212(c)(1)(B) of Pub. L. 105–115, set out as a note under section 355 of this title], whichever is later.


**Effective Date of 1968 Amendment**

Amendment by Pub. L. 90–399 effective on first day of thirteenth calendar month after July 13, 1968, see section 106(a) of Pub. L. 90–399, set out as an Effective Date and Transitional Provisions note under section 360b of this title.

**Effective Date of 1962 Amendment; Exceptions**

Amendment by Pub. L. 87–781 effective on first day of seventh calendar month following October 1962, see section 107 of Pub. L. 87–781, set out as a note under section 321 of this title.

**Effective Date of 1960 Amendment**


**Effective Date; Postponement**

Par. (a)(4) effective Jan. 1, 1940, see act June 23, 1939, ch. 242, 53 Stat. 853, set out as an Effective Date; Postponement in Certain Cases note under section 301 of this title.

**Transfer of Functions**

For transfer of functions of Federal Security Adminis-
trator to Secretary of Health, Education, and Welfare [now Health and Human Services], and of Food and Drug Administration in the Department of Agriculture to Federal Security Agency, see notes set out under section 321 of this title.

§ 352. Misbranded drugs and devices

A drug or device shall be deemed to be mis-

(a) False or misleading label

If its labeling is false or misleading in any par-
ticular. Health care economic information pro-
vided to a formulary committee, or other simi-
lar entity, in the course of the committee or the
entity’s responsibilities for the selection of drugs for managed care or other similar organizations, shall not be considered to be false or misleading under this paragraph if the health care economic information directly relates to an indication approved under section 355 of this title or under section 262(a) of title 42 for such drug and is based on competent and re-
liable scientific evidence. The requirements set forth in section 355(a) of this title or in section 262(a) of title 42 shall not apply to health care economic information provided to such a com-
mittee or entity in accordance with this para-

gaph. Information that is relevant to the sub-
stantiation of the health care economic infor-
mation presented pursuant to this paragraph shall be made available to the Secretary upon request. In this paragraph, the term “health care economic information” means any analysis that identifies, measures, or compares the eco-
nomic consequences, including the costs of the represented health outcomes, of the use of a drug to the use of another drug, to another health care intervention, or to no intervention.

(b) Package form; contents of label

If in package form unless it bears a label con-
taining (1) the name and place of business of the manufacturer, packer, or distributor; and (2) an accurate statement of the quantity of the con-
tents in terms of weight, measure, or numerical count: Provided, That under clause (2) of this paragraph reasonable variations shall be per-
mitted, and exemptions as to small packages shall be established, by regulations prescribed by the Secretary.

(c) Prominence of information on label

If any word, statement, or other information required by or under authority of this chapter to appear on the label or labeling is not promi-


(e) Designation of drugs or devices by estab-

§ 352. Misbranded drugs and devices

A drug or device shall be deemed to be mis-

(a) False or misleading label

If its labeling is false or misleading in any par-
ticular. Health care economic information pro-
vided to a formulary committee, or other simi-
lar entity, in the course of the committee or the
entity’s responsibilities for the selection of drugs for managed care or other similar organizations, shall not be considered to be false or misleading under this paragraph if the health care economic information directly relates to an indication approved under section 355 of this title or under section 262(a) of title 42 for such drug and is based on competent and re-
liable scientific evidence. The requirements set forth in section 355(a) of this title or in section 262(a) of title 42 shall not apply to health care economic information provided to such a com-
mittee or entity in accordance with this para-

gaph. Information that is relevant to the sub-
stantiation of the health care economic infor-
mation presented pursuant to this paragraph shall be made available to the Secretary upon request. In this paragraph, the term “health care economic information” means any analysis that identifies, measures, or compares the eco-
nomic consequences, including the costs of the represented health outcomes, of the use of a drug to the use of another drug, to another health care intervention, or to no intervention.

(b) Package form; contents of label

If in package form unless it bears a label con-
taining (1) the name and place of business of the manufacturer, packer, or distributor; and (2) an accurate statement of the quantity of the con-
tents in terms of weight, measure, or numerical count: Provided, That under clause (2) of this paragraph reasonable variations shall be per-
mitted, and exemptions as to small packages shall be established, by regulations prescribed by the Secretary.

(c) Prominence of information on label

If any word, statement, or other information required by or under authority of this chapter to appear on the label or labeling is not promi-


(e) Designation of drugs or devices by estab-
lished names

(1)(A) If it is a drug, unless its label bears, to
the exclusion of any other nonproprietary name (except the applicable systematic chemical name or the chemical formula)—

(i) the established name (as defined in sub-
paragraph (3)) of the drug, if there is such a name;

(ii) the established name and quantity or, if
determined to be appropriate by the Sec-

(1)(A) If it is a drug, unless its label bears, to
the exclusion of any other nonproprietary name (except the applicable systematic chemical name or the chemical formula)—

(i) the established name (as defined in sub-
paragraph (3)) of the drug, if there is such a name;

(ii) the established name and quantity or, if
determined to be appropriate by the Sec-

(iii) the established name of each inactive ingre-
dient listed in alphabetical order on the
outside container of the retail package and, if
determined to be appropriate by the Sec-

(iii) the established name of each inactive ingre-
dient listed in alphabetical order on the
outside container of the retail package and, if
determined to be appropriate by the Sec-

(B) For any prescription drug the established
name of such drug or ingredient, as the case

1997) or 2 years after the date on which the Secretary of Health and Human Services establishes the require-
ments described in subsection (c)(1)(B) [section 1212(c)(1)(B) of Pub. L. 105–115, set out as a note under section 355 of this title], whichever is later."